SCHEMBL16631485

SCHEMBL16631485

O=c1cc(F)n2cc([C@@H]3O[C@H](CO)C(O)[C@@H]3O)c(=O)nc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.40
GMNN O75496 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
STAT6 P42226 1/20 0.40
HIF1A Q16665 1/20 0.40
SLC5A2 P31639 6/20 0.38
PNP P00491 2/20 0.36
PYGM P11217 1/20 0.35
SLC28A1 O00337 1/20 0.35
SLC28A2 O43868 1/20 0.35
SLC29A1 Q99808 1/20 0.35
SLC28A3 Q9HAS3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631487 0.89 MAPT (0.41) KDM4EGMNNLMNAMAPTBLM
SCHEMBL16631484 0.87 PNP (0.39) KDM4EGMNNLMNAMAPTBLM
SCHEMBL16631644 0.83 PNP (0.36) KDM4EGMNNLMNAMAPTBLM
SCHEMBL16631702 0.81 PNP (0.35) KDM4EGMNNLMNAMAPTBLM
SCHEMBL16631646 0.81 PNP (0.35) KDM4EGMNNLMNAMAPTBLM
SCHEMBL18080258 0.81 P2RY2 (0.50)
SCHEMBL16631441 0.78 PYGM (0.38) KDM4EGMNNLMNAMAPTBLM
SCHEMBL16631442 0.78 SLC28A1 (0.46) KDM4EGMNNLMNAMAPTBLM
SCHEMBL16631648 0.77 LMNA (0.40) KDM4EGMNNLMNAMAPTBLM
SCHEMBL18081891 0.77 UMPS (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 KDM4E 4689/4885GMNN 556/4885LMNA 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.